SCHEMBL14770707

SCHEMBL14770707

COc1ccc(C(O)c2nc3cc(OC(F)(F)F)ccc3[nH]2)cc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 1/20 0.48
MLKL Q8NB16 2/20 0.45
RUNX1 Q01196 2/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CHEK2 O96017 1/20 0.40
PDE2A O00408 6/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
GABBR2 O75899 1/20 0.37
GABBR1 Q9UBS5 1/20 0.37
TRPV1 Q8NER1 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12065285 0.95 SCN10A (0.46) SCN10AMLKLRUNX1MEN1KMT2A
SCHEMBL12066573 0.93 SCN10A (0.46) SCN10AMLKLRUNX1KMT2APDE2A
SCHEMBL14770690 0.89 MLKL (0.52) MLKLMEN1KMT2ACHEK2GAA
SCHEMBL12066600 0.87 SCN10A (0.45) SCN10AMLKLRUNX1MEN1KMT2A
SCHEMBL14770699 0.87 MLKL (0.46) SCN10AMLKLMEN1KMT2ACHEK2
SCHEMBL14770638 0.87 SCN10A (0.52) SCN10ARUNX1PDE2ATRPV1
SCHEMBL14770709 0.86 MEN1 (0.48) SCN10AMLKLMEN1KMT2ACHEK2
SCHEMBL12066005 0.85 MEN1 (0.51) SCN10AMLKLMEN1KMT2APDE2A
SCHEMBL12065245 0.84 ALPL (0.44) SCN10AMLKLKMT2APDE2AGAA
SCHEMBL12066580 0.84 MLKL (0.43) SCN10AMLKLPDE2ATRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A SCN10A 85/4885MLKL 2378/4885RUNX1 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.